TY -的T1序列成像[11 c] PBR28建议增加神经炎症在阿尔茨海默病的恶化(P6.173) JF -神经学乔-神经学六世- 84 - 14补充SP - P6.173 AU -威廉Kreisl盟- Chul Hyoung Lyoo AU -莫妮卡魏盟-约瑟夫·雪盟金伯利Jenko首页 AU -谢丽尔·莫尔斯盟萨米Zoghbi AU -维克多派克AU - R·特纳AU -罗伯特•英尼斯Y1 - 2015/04/06 UR - //www.ez-admanager.com/content/84/14_Supplement/P6.173.abstract N2 -目的:确定炎症增加在阿尔茨海默病(AD)的进展。背景:18 kDa转运蛋白的蛋白质(TSPO)是一种存在的标志。我们的横断面研究显示,与c [11] PBR28绑定,宠物为TSPO放射性配体与临床严重程度的广告。广告设计/方法:患者七4轻度认知障碍(MCI)患者和7个年龄组进行了c [11] PBR28宠物在基线后,平均随访2.7年(范围1.2 - 5.7)。患者amyloid-positive和控制amyloid-negative在基线(11 c)加以成像。相对c [11] PBR28绑定60 - 90分钟post-injection计算使用小脑灰质pseudo-reference地区。广告和MCI患者进行统计分析。c组的差异[11]PBR28绑定在随访测定使用单变量方差分析与诊断和TSPO基因型固定因素作为协变量和基线绑定。回归系数计算来确定变化之间的相关性[11 c] PBR28绑定和认知得分的变化。结果:c [11] PBR28绑定在随访超过基线目标地区AD患者中,最大的变化(+ 18 [percnt])内嗅皮层。 Change in binding was within ±6[percnt] for controls. Corrected for baseline binding, patients showed greater [11C]PBR28 binding at follow-up than controls in superior and inferior parietal lobule, precuneus, occipital, and entorhinal cortex (p ≤ 0.04). Results were generally in agreement with and without partial volume correction. Change in [11C]PBR28 binding correlated with change in Clinical Dementia Rating scale in prefrontal cortex, inferior parietal lobule, precuneus, and superior and middle temporal cortex after partial volume correction (r 蠅 0.67, p ≤ 0.022). CONCLUSIONS: Progression of AD is associated with inflammation greater than that seen in normal aging. These results provide further evidence that inflammation increases in proportion to worsened clinical severity. [11C]PBR28 may have potential for monitoring progression in AD and tracking response to anti-inflammatory therapies.Disclosure: Dr. Kreisl has nothing to disclose. Dr. Lyoo has nothing to disclose. Dr. Wei has nothing to disclose. Dr. Snow has nothing to disclose. Dr. Jenko has nothing to disclose. Dr. Morse has nothing to disclose. Dr. Zoghbi has nothing to disclose. Dr. Pike has nothing to disclose. Dr. Turner has received personal compensation for activities with Pfizer Inc., Wyeth Pharmaceuticals, Janssen Pharmaceutica, Eli Lilly & Company, Baxter, and Ceregene as a consultant. Dr. Innis has nothing to disclose.Thursday, April 23 2015, 7:30 am-12:00 pm ER -